MeSH term
Frequency | Condition_Probility | Acute Disease | 12 | 0.0 |
Adolescent | 71 | 0.0 |
Adult | 258 | 0.0 |
Aged | 276 | 0.0 |
Aged, 80 and over | 106 | 1.0 |
Antifibrinolytic Agents/*blood | 2 | 40.0 |
Antiplasmin | 2 | 66.0 |
Antithrombin III | 4 | 7.0 |
Biological Markers/blood | 14 | 1.0 |
Case-Control Studies | 24 | 0.0 |
English Abstract | 125 | 1.0 |
Female | 293 | 0.0 |
Hemostasis | 3 | 2.0 |
Humans | 900 | 0.0 |
Logistic Models | 8 | 1.0 |
Male | 573 | 0.0 |
Peptide Fragments/*blood | 3 | 3.0 |
Plasmin | 5 | 38.0 |
Prothrombin | 2 | 4.0 |
Sensitivity and Specificity | 58 | 1.0 |
Statistics, Nonparametric | 7 | 0.0 |
Comparative Study | 181 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
Escherichia coli Infections/*microbiology | 2 | 12.0 |
Genes, Bacterial/*genetics | 2 | 22.0 |
Middle Aged | 344 | 0.0 |
Polymerase Chain Reaction | 17 | 0.0 |
Prevalence | 7 | 0.0 |
Research Support, Non-U.S. Gov't | 338 | 0.0 |
Urinary Tract Infections/*microbiology | 3 | 27.0 |
Drug Interactions | 2 | 0.0 |
Fibrinolysis | 13 | 8.0 |
Amino Acid Sequence | 27 | 0.0 |
DNA Primers | 4 | 0.0 |
Molecular Sequence Data | 40 | 0.0 |
Phylogeny | 3 | 0.0 |
Sequence Alignment | 4 | 0.0 |
Sequence Homology, Amino Acid | 9 | 0.0 |
Antiplasmin/metabolism | 9 | 33.0 |
Enzyme-Linked Immunosorbent Assay | 19 | 0.0 |
Plasmin/metabolism | 11 | 12.0 |
Plasminogen/*metabolism | 3 | 7.0 |
Plasminogen Activator Inhibitor 1/metabolism | 3 | 6.0 |
Synovial Fluid/*metabolism | 2 | 8.0 |
Time Factors | 40 | 0.0 |
Adenocarcinoma/*diagnosis/pathology | 4 | 44.0 |
Carcinoma, Squamous Cell/*diagnosis/pathology | 2 | 28.0 |
Cervix Neoplasms/*diagnosis/pathology | 6 | 75.0 |
False Negative Reactions | 12 | 8.0 |
Neoplasm Invasiveness | 11 | 0.0 |
Retrospective Studies | 39 | 1.0 |
Child | 34 | 0.0 |
Estrogen Receptor alpha | 3 | 1.0 |
Estrogen Receptor beta | 2 | 2.0 |
*Gene Expression | 4 | 0.0 |
Gestational Age | 4 | 0.0 |
Immunohistochemistry | 56 | 0.0 |
Infant | 16 | 0.0 |
Infant, Newborn | 10 | 0.0 |
Keratin/analysis | 12 | 5.0 |
Ki-67 Antigen/analysis | 2 | 0.0 |
Molecular Weight | 16 | 0.0 |
Prostate-Specific Antigen/analysis | 15 | 32.0 |
Protein-Tyrosine-Phosphatase/analysis | 2 | 40.0 |
Receptors, Androgen/analysis | 5 | 17.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 19 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 118 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 5 | 0.0 |
Alkaline Phosphatase/blood | 9 | 6.0 |
Cross-Sectional Studies | 6 | 0.0 |
Prostate/enzymology | 33 | 62.0 |
Prostate-Specific Antigen/*blood | 30 | 34.0 |
Prostatic Neoplasms/diagnosis | 3 | 50.0 |
Tumor Markers, Biological/blood | 13 | 8.0 |
Acid Phosphatase/metabolism | 19 | 29.0 |
Animals | 128 | 0.0 |
Binding Sites | 6 | 0.0 |
Blotting, Western | 9 | 0.0 |
COS Cells | 3 | 0.0 |
Electrophoretic Mobility Shift Assay | 2 | 0.0 |
Genetic Vectors | 5 | 0.0 |
Phosphorylation | 10 | 0.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
Rats | 27 | 0.0 |
Acute-Phase Proteins/*analysis | 10 | 12.0 |
*Antigens, Neoplasm | 25 | 13.0 |
Biological Markers/*blood | 2 | 1.0 |
*Lectins, C-Type | 25 | 14.0 |
Prospective Studies | 31 | 0.0 |
Reference Values | 31 | 0.0 |
*Tumor Markers, Biological | 27 | 14.0 |
RNA, Messenger/analysis | 8 | 0.0 |
Inflammation/pathology | 2 | 3.0 |
Antineoplastic Agents, Hormonal/therapeutic use | 2 | 4.0 |
Drug Resistance, Neoplasm | 2 | 0.0 |
Phosphopyruvate Hydratase/blood | 2 | 13.0 |
Prostate-Specific Antigen/blood | 12 | 13.0 |
Prostatic Neoplasms/blood/*diagnosis | 6 | 60.0 |
Protein-Tyrosine-Phosphatase/blood | 2 | 50.0 |
ROC Curve | 10 | 5.0 |
Testosterone/blood | 10 | 1.0 |
Acid Phosphatase/analysis | 36 | 51.0 |
Carcinoembryonic Antigen/analysis | 5 | 4.0 |
Carrier Proteins/analysis | 2 | 2.0 |
*Immunophenotyping | 2 | 1.0 |
Intermediate Filament Proteins/analysis | 3 | 7.0 |
Nuclear Proteins/analysis | 2 | 1.0 |
Immunoglobulin A/metabolism | 2 | 3.0 |
Tissue Plasminogen Activator/blood | 5 | 4.0 |
Urinary Plasminogen Activator/blood | 3 | 23.0 |
Tumor Markers, Biological/*analysis/blood | 3 | 15.0 |
Cattle | 13 | 0.0 |
Reproducibility of Results | 11 | 0.0 |
Microscopy, Electron | 18 | 0.0 |
Cell Line | 32 | 0.0 |
Polynucleotide Adenylyltransferase/*metabolism | 5 | 71.0 |
Catalytic Domain | 2 | 0.0 |
Enzyme Activation | 6 | 0.0 |
Hydrogen-Ion Concentration | 10 | 0.0 |
Hydrolysis | 6 | 0.0 |
Kinetics | 14 | 0.0 |
Models, Molecular | 4 | 0.0 |
Peptide Hydrolases/metabolism | 8 | 5.0 |
Recombinant Proteins/chemistry/metabolism | 2 | 0.0 |
Biopsy | 19 | 1.0 |
Colposcopy | 11 | 55.0 |
DNA, Viral/genetics | 3 | 1.0 |
In Situ Hybridization | 8 | 0.0 |
Acid Phosphatase/*metabolism | 19 | 65.0 |
Prostate/*enzymology | 90 | 74.0 |
Antigens, Heterophile/*immunology | 2 | 16.0 |
Mice | 52 | 0.0 |
Protein-Tyrosine-Phosphatase/immunology | 3 | 37.0 |
Treatment Outcome | 11 | 0.0 |
Cervix Neoplasms/*pathology | 8 | 36.0 |
Cervix Uteri/pathology | 7 | 38.0 |
*Colposcopy | 6 | 66.0 |
Follow-Up Studies | 39 | 1.0 |
Predictive Value of Tests | 43 | 2.0 |
*Vaginal Smears | 30 | 66.0 |
Cervical Intraepithelial Neoplasia/diagnosis/virology | 2 | 100.0 |
DNA, Viral/*analysis | 14 | 14.0 |
Papillomavirus Infections/*diagnosis | 3 | 100.0 |
Papillomavirus, Human/genetics/*isolation & purification | 3 | 20.0 |
Quality Control | 7 | 3.0 |
Tumor Virus Infections/*diagnosis | 9 | 60.0 |
Cell Adhesion | 3 | 0.0 |
Cell Differentiation | 3 | 0.0 |
Cell Division | 9 | 0.0 |
Cell Separation | 2 | 0.0 |
Cells, Cultured | 11 | 0.0 |
Antiplasmin/analysis | 7 | 18.0 |
Child, Preschool | 21 | 0.0 |
Fibrin/metabolism | 3 | 4.0 |
Fibrin Fibrinogen Degradation Products/analysis | 7 | 5.0 |
Longitudinal Studies | 4 | 0.0 |
Peptide Fragments/blood | 2 | 1.0 |
Peptide Hydrolases/blood | 3 | 6.0 |
Plasmin/analysis | 9 | 20.0 |
Thrombin/metabolism | 4 | 2.0 |
*Hemostasis | 3 | 2.0 |
Risk Factors | 31 | 0.0 |
Thrombosis/etiology | 2 | 3.0 |
Chromatography, Affinity | 8 | 1.0 |
Chromatography, High Pressure Liquid | 6 | 0.0 |
Cloning, Molecular | 17 | 0.0 |
Disease Progression | 4 | 0.0 |
Linear Models | 3 | 0.0 |
Observer Variation | 2 | 1.0 |
Patient Selection | 3 | 1.0 |
Plasminogen/metabolism | 2 | 5.0 |
Disease Models, Animal | 3 | 0.0 |
In Situ Nick-End Labeling | 2 | 0.0 |
Orchiectomy | 14 | 13.0 |
Rats, Wistar | 2 | 0.0 |
Actins/analysis | 3 | 1.0 |
Cell Differentiation/drug effects | 2 | 0.0 |
Cell Division/drug effects | 4 | 0.0 |
Pregnancy | 19 | 0.0 |
Receptors, Estrogen/analysis | 2 | 0.0 |
Vimentin/analysis | 6 | 2.0 |
Age Factors | 12 | 0.0 |
Cohort Studies | 12 | 0.0 |
Patient Compliance/*statistics & numerical data | 2 | 18.0 |
Vaginal Smears/*utilization | 2 | 66.0 |
Victoria | 2 | 33.0 |
Plasminogen Activator Inhibitor 1/blood | 6 | 5.0 |
Prognosis | 60 | 0.0 |
In Vitro | 9 | 0.0 |
Models, Theoretical | 2 | 1.0 |
Exercise/*physiology | 3 | 0.0 |
Fibrinolysis/*physiology | 8 | 10.0 |
Flow Cytometry | 4 | 0.0 |
Plasmin/*metabolism | 4 | 15.0 |
Thrombin/*metabolism | 2 | 2.0 |
Heart Rate | 3 | 1.0 |
Monitoring, Physiologic | 3 | 3.0 |
Age Distribution | 4 | 1.0 |
Hysterectomy | 2 | 2.0 |
Neoplasm Staging | 60 | 2.0 |
Antifibrinolytic Agents/blood | 2 | 13.0 |
*Antiplasmin | 8 | 19.0 |
Prothrombin/analysis | 3 | 4.0 |
Solubility | 4 | 0.0 |
*Blood Coagulation | 5 | 2.0 |
Analysis of Variance | 7 | 0.0 |
Cancer Vaccines/immunology | 2 | 10.0 |
Lymphocyte Activation/immunology | 2 | 0.0 |
Peptide Fragments/immunology | 2 | 0.0 |
Prostatic Neoplasms/enzymology/immunology | 2 | 100.0 |
Lymphatic Metastasis | 13 | 1.0 |
Prostatic Neoplasms/*pathology | 9 | 7.0 |
CA-19-9 Antigen/blood | 2 | 8.0 |
Tumor Markers, Biological/*blood | 62 | 13.0 |
Biological Markers/analysis | 3 | 0.0 |
Fibrinolysis/physiology | 7 | 15.0 |
Platelet Activation | 2 | 1.0 |
Prothrombin/metabolism | 5 | 6.0 |
beta-Thromboglobulin/metabolism | 2 | 3.0 |
Acid Phosphatase/*biosynthesis | 2 | 33.0 |
Cell Differentiation/physiology | 4 | 0.0 |
Phenotype | 11 | 0.0 |
Prostate-Specific Antigen/*biosynthesis | 2 | 20.0 |
Adenocarcinoma/metabolism/*pathology | 2 | 3.0 |
Prostatic Neoplasms/metabolism/*pathology | 8 | 11.0 |
Tumor Markers, Biological/metabolism | 3 | 0.0 |
Cell Culture Techniques/*methods | 2 | 2.0 |
Karyotyping | 2 | 0.0 |
Mice, SCID | 10 | 1.0 |
Prostatic Neoplasms/genetics/*pathology | 2 | 10.0 |
Androgens/pharmacology | 3 | 6.0 |
Neoplasm Transplantation | 10 | 0.0 |
Cervix Neoplasms/*epidemiology/prevention & control | 2 | 66.0 |
*Developing Countries | 2 | 6.0 |
Vaginal Smears | 28 | 43.0 |
Neoplasm Proteins/*analysis | 2 | 0.0 |
Prostatic Hyperplasia/metabolism | 7 | 21.0 |
Prostatic Neoplasms/*chemistry | 2 | 14.0 |
Gene Expression | 11 | 0.0 |
Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Prostatic Neoplasms/genetics/*metabolism | 2 | 7.0 |
RNA, Messenger/genetics/metabolism | 5 | 0.0 |
Acute-Phase Proteins/*metabolism | 2 | 3.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/genetics | 2 | 3.0 |
Feasibility Studies | 4 | 1.0 |
France/epidemiology | 3 | 2.0 |
Cervix Uteri/cytology/*pathology | 2 | 100.0 |
Odds Ratio | 6 | 0.0 |
Blood Coagulation | 3 | 1.0 |
Leukocyte Count | 3 | 0.0 |
*Antifibrinolytic Agents | 11 | 52.0 |
Disease-Free Survival | 3 | 0.0 |
Myocardial Infarction/*blood/*therapy | 2 | 66.0 |
Point Mutation | 2 | 0.0 |
Recurrence | 4 | 0.0 |
Prostatic Hyperplasia/*metabolism | 2 | 4.0 |
Prostatic Neoplasms/chemistry/*metabolism | 2 | 66.0 |
Intraoperative Period | 2 | 3.0 |
Staining and Labeling/*methods | 2 | 10.0 |
Cell Survival/drug effects | 4 | 0.0 |
Immunoblotting | 6 | 0.0 |
Isoenzymes/metabolism | 2 | 0.0 |
Cervical Intraepithelial Neoplasia/diagnosis/epidemiology | 2 | 100.0 |
Cervix Dysplasia/diagnosis/epidemiology | 2 | 100.0 |
Cervix Neoplasms/*diagnosis/*epidemiology | 4 | 100.0 |
United States/epidemiology | 5 | 1.0 |
Vaginal Smears/*statistics & numerical data | 3 | 100.0 |
Plasminogen Activator Inhibitor 1/*blood | 3 | 9.0 |
Fibrin Fibrinogen Degradation Products/metabolism | 10 | 11.0 |
*Fibrinolysis | 13 | 9.0 |
Alleles | 3 | 0.0 |
Fatal Outcome | 3 | 0.0 |
Echocardiography, Doppler | 2 | 5.0 |
Pilot Projects | 4 | 0.0 |
Fibrinolysis/*drug effects | 4 | 6.0 |
Anti-HIV Agents/*pharmacology | 2 | 1.0 |
Hamsters | 7 | 0.0 |
*N-Glycosyl Hydrolases | 26 | 47.0 |
Plant Proteins/*pharmacology | 5 | 26.0 |
Models, Biological | 5 | 0.0 |
Dose-Response Relationship, Drug | 9 | 0.0 |
Incidence | 13 | 1.0 |
Risk Assessment | 4 | 0.0 |
Laboratories/*standards | 2 | 8.0 |
Mass Screening | 8 | 4.0 |
*Vaginal Smears/standards | 4 | 80.0 |
Italy/epidemiology | 2 | 0.0 |
Neoplasm, Residual | 2 | 2.0 |
T-Lymphocytes/immunology | 4 | 0.0 |
Antigens, Neoplasm/metabolism | 3 | 4.0 |
Lymph Nodes/pathology | 3 | 1.0 |
Multivariate Analysis | 16 | 1.0 |
Survival Analysis | 8 | 0.0 |
Administration, Inhalation | 4 | 2.0 |
Nitric Oxide/*administration & dosage | 2 | 66.0 |
Cell Membrane/enzymology | 3 | 1.0 |
Drug Carriers | 2 | 1.0 |
Liposomes | 2 | 0.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Phosphatidic Acids/*metabolism/pharmacology | 2 | 100.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
Substrate Specificity | 12 | 0.0 |
Transfection | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 4 | 0.0 |
Biopsy, Needle | 9 | 2.0 |
Flutamide/therapeutic use | 4 | 44.0 |
Leuprolide/therapeutic use | 2 | 15.0 |
Acid Phosphatase/*blood | 106 | 85.0 |
Prostate/*metabolism | 5 | 6.0 |
Diagnosis, Differential | 27 | 1.0 |
Keratin/metabolism | 3 | 2.0 |
Prostate-Specific Antigen/metabolism | 9 | 25.0 |
Vaginal Smears/*methods | 4 | 44.0 |
Genotype | 4 | 0.0 |
Immunohistochemistry/methods | 5 | 0.0 |
Polymerase Chain Reaction/methods | 3 | 0.0 |
Tumor Cells, Cultured | 22 | 0.0 |
Prostatic Neoplasms/*diagnosis | 28 | 59.0 |
Injections, Subcutaneous | 4 | 1.0 |
Respiratory Function Tests | 2 | 1.0 |
Acid Phosphatase/*analysis | 40 | 80.0 |
Immunoenzyme Techniques | 124 | 3.0 |
Prostate-Specific Antigen/*analysis | 5 | 21.0 |
Apoptosis | 3 | 0.0 |
Prostate/*pathology | 2 | 8.0 |
Tumor Markers, Biological/*metabolism | 6 | 1.0 |
Protein Biosynthesis | 8 | 0.0 |
Virus Replication | 3 | 0.0 |
Fluorescent Dyes | 2 | 0.0 |
Staining and Labeling | 17 | 2.0 |
*Liver Transplantation | 2 | 1.0 |
Preoperative Care | 4 | 2.0 |
Pulmonary Wedge Pressure | 2 | 14.0 |
Quality Assurance, Health Care | 2 | 11.0 |
Serotyping | 4 | 1.0 |
Swine | 5 | 0.0 |
*Blood Pressure | 2 | 1.0 |
Adenocarcinoma/etiology/pathology/virology | 2 | 100.0 |
Carcinoma, Squamous Cell/etiology/pathology/virology | 2 | 100.0 |
Cervix Neoplasms/*etiology/pathology/virology | 2 | 100.0 |
Cervix Uteri/*virology | 2 | 20.0 |
Chronic Disease | 13 | 0.0 |
Papillomavirus, Human/classification/genetics/*isolation & purification | 3 | 37.0 |
Papovaviridae Infections/*complications | 2 | 16.0 |
Population Surveillance | 2 | 1.0 |
Tumor Virus Infections/*complications | 2 | 7.0 |
Brachytherapy | 2 | 20.0 |
Neoplasm Proteins/*blood | 2 | 3.0 |
Palladium/*therapeutic use | 3 | 100.0 |
Prostatic Neoplasms/*blood/pathology/*radiotherapy | 2 | 66.0 |
Radioisotopes/*therapeutic use | 3 | 50.0 |
Treatment Failure | 3 | 1.0 |
Virus Replication/drug effects | 2 | 0.0 |
Cell Membrane/metabolism | 3 | 0.0 |
Diglycerides/*metabolism | 2 | 11.0 |
Fluorescent Antibody Technique | 15 | 0.0 |
Phosphatidate Phosphatase/genetics/*metabolism | 2 | 100.0 |
Phospholipase D/*metabolism | 2 | 2.0 |
Signal Transduction | 4 | 0.0 |
Neoplasm Metastasis | 18 | 1.0 |
Drug Resistance | 2 | 0.0 |
Amylases/blood | 2 | 9.0 |
C-Reactive Protein/metabolism | 3 | 1.0 |
Lipase/blood | 3 | 4.0 |
Mutation | 4 | 0.0 |
*HIV-1 | 4 | 0.0 |
RNA, Ribosomal/metabolism | 2 | 11.0 |
Recombinant Proteins/chemistry/pharmacology | 2 | 8.0 |
Down-Regulation | 2 | 0.0 |
*Gene Expression Regulation | 2 | 0.0 |
*Prostatic Secretory Proteins | 41 | 46.0 |
*Hemodilution | 2 | 40.0 |
Postoperative Period | 2 | 0.0 |
alpha-Macroglobulins/analysis | 2 | 5.0 |
Finland/epidemiology | 2 | 1.0 |
Random Allocation | 3 | 0.0 |
Gels | 2 | 2.0 |
Rabbits | 22 | 0.0 |
Specific Pathogen-Free Organisms | 2 | 2.0 |
Acid Phosphatase/blood | 49 | 68.0 |
*Enzyme Tests | 12 | 18.0 |
Prostatic Hyperplasia/*diagnosis | 3 | 100.0 |
Base Sequence | 27 | 0.0 |
DNA, Complementary | 6 | 0.0 |
Guinea Pigs | 2 | 0.0 |
Phosphatidate Phosphatase/*genetics/metabolism | 2 | 100.0 |
Protein Processing, Post-Translational | 3 | 0.0 |
Cell-Free System | 2 | 0.0 |
Carcinoembryonic Antigen/blood | 4 | 7.0 |
Lectins/*blood | 2 | 33.0 |
False Positive Reactions | 8 | 3.0 |
Mass Screening/*methods | 4 | 7.0 |
Antibody Affinity | 3 | 1.0 |
Antibody Specificity | 10 | 0.0 |
Immunization | 3 | 0.0 |
Mice, Inbred BALB C | 12 | 0.0 |
Phospholipase D/metabolism | 2 | 7.0 |
Myocardium/pathology | 2 | 2.0 |
Antibodies, Monoclonal/*immunology | 6 | 0.0 |
Dogs | 7 | 0.0 |
*Immunoenzyme Techniques | 26 | 20.0 |
Precipitin Tests | 4 | 0.0 |
Species Specificity | 15 | 0.0 |
Antithrombin III/analysis | 9 | 4.0 |
Immunoassay | 6 | 2.0 |
von Willebrand Factor/analysis | 2 | 0.0 |
Carcinoma, Squamous Cell/*diagnosis | 3 | 37.0 |
Cervical Intraepithelial Neoplasia/*diagnosis | 4 | 80.0 |
Cervix Neoplasms/*diagnosis | 9 | 69.0 |
Cytodiagnosis | 3 | 11.0 |
Luteinizing Hormone/blood | 5 | 0.0 |
Prostatic Neoplasms/*blood/drug therapy/pathology | 2 | 100.0 |
Radioimmunoassay | 42 | 2.0 |
Gene Amplification | 3 | 0.0 |
European Continental Ancestry Group | 2 | 0.0 |
Insulin Resistance | 2 | 1.0 |
Biological Markers | 7 | 0.0 |
Escherichia coli/*genetics | 2 | 2.0 |
Genes, Reporter | 2 | 0.0 |
*Protein Biosynthesis | 3 | 0.0 |
Cervix Neoplasms/*epidemiology/pathology | 2 | 100.0 |
Cervix Uteri/*pathology | 6 | 50.0 |
Equipment Design | 2 | 1.0 |
United States | 4 | 0.0 |
Hela Cells | 3 | 0.0 |
Proteins/*metabolism | 4 | 0.0 |
Cervix Neoplasms/pathology | 2 | 18.0 |
Delayed-Action Preparations | 2 | 1.0 |
Precancerous Conditions/pathology | 2 | 9.0 |
Progesterone Congeners/*administration & dosage | 2 | 100.0 |
Cell Cycle | 2 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Tumor Markers, Biological/*analysis | 44 | 4.0 |
Cervical Intraepithelial Neoplasia/*diagnosis/virology | 2 | 100.0 |
Cervix Neoplasms/*diagnosis/virology | 2 | 100.0 |
DNA, Viral/analysis | 6 | 1.0 |
DNA, Complementary/*genetics | 2 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Prostate/metabolism/pathology | 4 | 21.0 |
Proteins/*analysis | 22 | 14.0 |
Semen/*chemistry | 2 | 7.0 |
Papovaviridae Infections/*diagnosis | 3 | 50.0 |
Prostate/*metabolism/pathology | 2 | 15.0 |
Prostatic Hyperplasia/*metabolism/pathology | 2 | 6.0 |
Prostatic Neoplasms/*metabolism/pathology | 4 | 5.0 |
Antibody Formation | 3 | 0.0 |
Immunoglobulin G/biosynthesis | 2 | 1.0 |
Leukemia, T-Cell, Acute/*drug therapy | 2 | 66.0 |
Macaca fascicularis | 4 | 1.0 |
Tissue Distribution | 9 | 0.0 |
Transplantation, Heterologous | 8 | 0.0 |
Injections, Intravenous | 3 | 0.0 |
Acute-Phase Proteins/*genetics | 2 | 15.0 |
*Multigene Family | 2 | 0.0 |
Pulmonary Surfactant-Associated Protein A | 2 | 6.0 |
Pulmonary Surfactant-Associated Protein D | 2 | 12.0 |
Pulmonary Surfactant-Associated Proteins | 2 | 5.0 |
Androgen Antagonists/therapeutic use | 4 | 19.0 |
Drug Administration Schedule | 3 | 0.0 |
Drug Therapy, Combination | 3 | 0.0 |
Lipids/*metabolism | 2 | 0.0 |
Prostatic Neoplasms/blood/*drug therapy | 6 | 40.0 |
alpha-Fetoproteins/*analysis | 3 | 0.0 |
Proportional Hazards Models | 6 | 0.0 |
Registries | 3 | 1.0 |
Risk | 2 | 0.0 |
Prostate | 5 | 27.0 |
Prostatectomy | 12 | 14.0 |
Cheek | 2 | 7.0 |
Drug Screening Assays, Antitumor | 2 | 0.0 |
Immunotoxins/*therapeutic use | 4 | 8.0 |
Plant Proteins/*therapeutic use | 3 | 50.0 |
Irrigation/*methods | 2 | 100.0 |
Peptide Fragments/metabolism | 2 | 0.0 |
Prostate-Specific Antigen/biosynthesis | 2 | 15.0 |
Pulmonary Alveolar Proteinosis/*immunology | 2 | 100.0 |
Acid Phosphatase/*genetics | 4 | 10.0 |
Prostatic Neoplasms/*enzymology | 20 | 46.0 |
RNA, Messenger/metabolism | 9 | 0.0 |
Isoenzymes/genetics | 2 | 0.0 |
Organ Specificity | 4 | 0.0 |
Sequence Analysis, DNA | 4 | 0.0 |
HIV-1/*drug effects | 2 | 1.0 |
Family Practice | 2 | 6.0 |
Blood Coagulation/*physiology | 6 | 5.0 |
Tissue Plasminogen Activator/metabolism | 2 | 5.0 |
*Circadian Rhythm | 5 | 2.0 |
Cervix Dysplasia/*diagnosis | 3 | 75.0 |
Antigens/analysis | 7 | 5.0 |
Peptide Hydrolases/analysis | 7 | 5.0 |
Thrombin/*biosynthesis | 2 | 6.0 |
Alkaline Phosphatase/*blood | 7 | 20.0 |
Bone Neoplasms/enzymology/*secondary | 2 | 100.0 |
Prostatic Neoplasms/enzymology/*pathology | 3 | 33.0 |
*Prostatectomy | 5 | 17.0 |
Prostate/*physiology | 2 | 20.0 |
Transcription, Genetic | 4 | 0.0 |
Lipoproteins, HDL Cholesterol/blood | 2 | 0.0 |
Lipoproteins, LDL Cholesterol/blood | 2 | 0.0 |
Osmolar Concentration | 4 | 0.0 |
Metribolone/pharmacology | 2 | 8.0 |
Thymidine/metabolism | 2 | 0.0 |
Mutagenesis | 2 | 0.0 |
Automation | 2 | 3.0 |
Antibodies, Monoclonal | 10 | 0.0 |
Antineoplastic Agents, Phytogenic/*therapeutic use | 3 | 9.0 |
Clinical Trials | 7 | 0.0 |
*Histological Techniques | 3 | 37.0 |
Immunohistochemistry/*methods | 2 | 2.0 |
Cervix Neoplasms/*epidemiology/etiology | 2 | 66.0 |
Parity | 3 | 2.0 |
Blotting, Southern | 6 | 0.0 |
Papovaviridae Infections/complications/*epidemiology | 2 | 40.0 |
Tumor Virus Infections/complications/*epidemiology | 2 | 50.0 |
Rats, Inbred Strains | 5 | 0.0 |
Nucleic Acid Conformation | 2 | 0.0 |
Nucleic Acid Hybridization | 10 | 0.0 |
Adenocarcinoma/*enzymology | 3 | 12.0 |
Prostatic Hyperplasia/*enzymology | 6 | 75.0 |
Chromosome Mapping | 4 | 0.0 |
DNA Probes | 3 | 0.0 |
Plasmids | 5 | 0.0 |
Propranolol/pharmacology | 2 | 4.0 |
Proteins/metabolism | 2 | 0.0 |
Cervix Diseases/*diagnosis | 3 | 75.0 |
Antifibrinolytic Agents/metabolism | 2 | 9.0 |
Antithrombin III/metabolism | 6 | 5.0 |
Double-Blind Method | 4 | 0.0 |
Fibrinogen/*metabolism | 2 | 2.0 |
Partial Thromboplastin Time | 2 | 1.0 |
Androgens/*metabolism | 3 | 5.0 |
Keratin/*analysis | 3 | 10.0 |
Acid Phosphatase/*immunology | 12 | 92.0 |
Cross Reactions | 6 | 0.0 |
Prostate/*immunology | 3 | 75.0 |
Prostatic Neoplasms/*blood/*pathology | 3 | 50.0 |
Prostatic Neoplasms/chemistry/*pathology | 3 | 25.0 |
DNA, Viral/isolation & purification | 2 | 8.0 |
Conserved Sequence | 3 | 0.0 |
Homeostasis | 2 | 0.0 |
RNA Splicing | 2 | 0.0 |
Androgen Antagonists/*therapeutic use | 5 | 13.0 |
Testicular Neoplasms/*diagnosis | 3 | 50.0 |
Protein Biosynthesis/drug effects | 3 | 4.0 |
Intestinal Mucosa/pathology | 2 | 3.0 |
Anti-Bacterial Agents/administration & dosage/therapeutic use | 2 | 50.0 |
*Mass Screening | 5 | 9.0 |
Tumor Virus Infections/*epidemiology | 2 | 50.0 |
Combined Modality Therapy | 9 | 0.0 |
Prostate/pathology | 4 | 17.0 |
Prostatic Neoplasms/*pathology/therapy | 2 | 50.0 |
Tumor Markers, Biological/analysis | 8 | 1.0 |
Mice, Transgenic | 2 | 0.0 |
Rats, Sprague-Dawley | 3 | 0.0 |
Hemodynamic Processes/drug effects | 2 | 1.0 |
Respiratory Distress Syndrome, Adult/*drug therapy/physiopathology | 2 | 100.0 |
Chromosome Aberrations | 4 | 0.0 |
Colony-Forming Units Assay | 2 | 0.0 |
Mice, Nude | 11 | 0.0 |
Hormones/*therapeutic use | 2 | 16.0 |
Protein Binding | 6 | 0.0 |
Evaluation Studies | 15 | 2.0 |
Adenocarcinoma/*diagnosis | 3 | 25.0 |
Prostate/enzymology/pathology | 3 | 100.0 |
Prostatic Hyperplasia/diagnosis | 15 | 68.0 |
Prostatic Neoplasms/*diagnosis/pathology | 10 | 66.0 |
Blood Sedimentation | 2 | 1.0 |
Cell Division/drug effects/physiology | 2 | 0.0 |
Dihydrotestosterone/metabolism | 2 | 3.0 |
Hemodynamic Processes/*drug effects | 3 | 2.0 |
*Bacterial Adhesion | 3 | 6.0 |
Cervix Dysplasia/*pathology | 3 | 100.0 |
Diagnostic Errors | 2 | 2.0 |
Vaginal Smears/*standards | 3 | 75.0 |
Methods | 5 | 2.0 |
Carcinoembryonic Antigen/*blood | 2 | 8.0 |
Regression Analysis | 8 | 0.0 |
*Nerve Tissue Proteins | 2 | 0.0 |
Prostate/*secretion | 2 | 50.0 |
Hyperplasia | 4 | 1.0 |
Organ Size | 2 | 1.0 |
Prostatic Neoplasms/*diagnosis/enzymology | 7 | 100.0 |
Reagent Kits, Diagnostic/*standards | 5 | 21.0 |
Chromatography, Gel | 6 | 0.0 |
Solutions | 2 | 1.0 |
Spectrometry, Fluorescence | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay/*methods | 2 | 1.0 |
Peptide Fragments/analysis | 3 | 1.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 3 | 0.0 |
Japan | 3 | 0.0 |
Survival Rate | 8 | 0.0 |
Proteins/analysis | 6 | 4.0 |
Antibodies, Monoclonal/analysis | 2 | 2.0 |
Antiplasmin/*analysis | 2 | 40.0 |
Plasmin/*analysis | 2 | 18.0 |
Antifibrinolytic Agents/*metabolism | 2 | 33.0 |
Blood Coagulation Tests | 2 | 1.0 |
Cervix Neoplasms/*immunology | 2 | 10.0 |
CHO Cells | 3 | 0.0 |
Pituitary Gland/metabolism | 2 | 3.0 |
Absorption | 2 | 1.0 |
Administration, Oral | 2 | 0.0 |
Half-Life | 6 | 1.0 |
Prostatic Neoplasms/*drug therapy/mortality | 3 | 50.0 |
Cell Survival | 2 | 0.0 |
Hormones/blood | 4 | 3.0 |
Polynucleotide Adenylyltransferase/metabolism | 2 | 100.0 |
Drug Combinations | 3 | 0.0 |
Acid Phosphatase/immunology/*isolation & purification | 3 | 100.0 |
Electrophoresis, Polyacrylamide Gel | 17 | 0.0 |
Receptors, Estrogen/*analysis | 2 | 0.0 |
Receptors, Progesterone/*analysis | 2 | 0.0 |
*Mutation | 2 | 0.0 |
Bronchoalveolar Lavage Fluid/*cytology | 2 | 4.0 |
Lymphocytes/*classification/immunology | 2 | 20.0 |
Papio | 2 | 1.0 |
Hemostasis/*physiology | 2 | 3.0 |
*Papillomavirus, Human | 3 | 9.0 |
Lung/*metabolism | 3 | 3.0 |
Antigens/*analysis | 14 | 16.0 |
Formaldehyde | 3 | 3.0 |
Aging/*metabolism | 2 | 0.0 |
Acid Phosphatase/blood/*metabolism | 4 | 100.0 |
Antigens, CD19 | 3 | 1.0 |
Antigens, Differentiation, B-Lymphocyte/*immunology | 2 | 2.0 |
DNA, Neoplasm/analysis | 2 | 0.0 |
Injections, Intraperitoneal | 2 | 1.0 |
Plant Proteins/administration & dosage/*therapeutic use | 2 | 100.0 |
Proteins/*genetics | 3 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Antigens, Neoplasm/analysis | 17 | 5.0 |
Antineoplastic Agents, Phytogenic/*pharmacology | 2 | 1.0 |
Blotting, Northern | 8 | 0.0 |
Infusions, Intravenous | 3 | 0.0 |
Bone Neoplasms/diagnosis/secondary | 2 | 66.0 |
Prostatic Neoplasms/*blood/diagnosis | 4 | 80.0 |
RNA, Messenger/genetics | 5 | 0.0 |
Buffers | 2 | 1.0 |
Drug Stability | 3 | 1.0 |
Questionnaires | 3 | 0.0 |
Taiwan/epidemiology | 2 | 1.0 |
Adenocarcinoma/*chemistry/pathology | 2 | 4.0 |
Phosphopyruvate Hydratase/*analysis | 3 | 15.0 |
Prostatic Neoplasms/*chemistry/pathology | 2 | 9.0 |
Plasminogen Activators/*blood | 2 | 25.0 |
Acid Phosphatase/*analysis/blood | 3 | 100.0 |
Bone Neoplasms/radionuclide imaging/*secondary | 4 | 66.0 |
Bone and Bones/radionuclide imaging | 3 | 30.0 |
Prostate-Specific Antigen/*metabolism | 4 | 19.0 |
Indium Radioisotopes/*diagnostic use | 2 | 11.0 |
Prostatic Neoplasms/pathology/*radionuclide imaging | 2 | 100.0 |
Bone Neoplasms/secondary | 7 | 15.0 |
Castration | 3 | 6.0 |
Collagen/*analysis | 3 | 8.0 |
Acetic Acid | 3 | 16.0 |
Acetic Acids/*diagnostic use | 3 | 100.0 |
Cervix Dysplasia/diagnosis | 3 | 100.0 |
Prostatic Hyperplasia/enzymology | 16 | 88.0 |
*Reagent Kits, Diagnostic | 2 | 3.0 |
Alkaline Phosphatase/*analysis | 2 | 40.0 |
Antibodies, Monoclonal/diagnostic use | 5 | 0.0 |
Epitopes | 2 | 0.0 |
Isoenzymes/*analysis | 4 | 8.0 |
Placenta/*enzymology | 3 | 3.0 |
L-Lactate Dehydrogenase/*metabolism | 2 | 14.0 |
Semen/*enzymology | 2 | 10.0 |
Prostatic Hyperplasia/*blood | 4 | 44.0 |
Prostatic Neoplasms/*blood | 10 | 38.0 |
*Chromosomes, Human, Pair 2 | 2 | 0.0 |
Restriction Mapping | 3 | 0.0 |
Pyelonephritis/microbiology | 2 | 50.0 |
Bone and Bones/*radionuclide imaging | 5 | 41.0 |
Testosterone/*blood | 2 | 0.0 |
Adhesins, Escherichia coli | 6 | 75.0 |
Bacterial Outer Membrane Proteins/*genetics | 3 | 37.0 |
Pyelonephritis/*microbiology | 2 | 40.0 |
Prostatic Neoplasms/*metabolism | 7 | 5.0 |
Tumor Markers, Biological | 5 | 1.0 |
Forecasting | 3 | 0.0 |
Leukemia/enzymology | 3 | 42.0 |
Severity of Illness Index | 3 | 0.0 |
Nigeria/epidemiology | 2 | 6.0 |
RNA Precursors/*metabolism | 2 | 10.0 |
Sequence Homology, Nucleic Acid | 4 | 0.0 |
Collagen/*metabolism | 2 | 1.0 |
Hemostasis/physiology | 2 | 6.0 |
Specimen Handling | 4 | 4.0 |
*Genes, Structural | 3 | 0.0 |
Hybrid Cells | 2 | 0.0 |
Epithelial Cells | 3 | 0.0 |
S100 Proteins/*analysis | 6 | 13.0 |
Neoplasm Recurrence, Local | 6 | 1.0 |
Peptides/*blood | 4 | 5.0 |
Prostatic Neoplasms/*diagnosis/pathology/therapy | 2 | 66.0 |
Estrogens/therapeutic use | 3 | 25.0 |
Cervix Neoplasms/*prevention & control | 2 | 50.0 |
Isoenzymes/blood | 4 | 6.0 |
Cervix Uteri/microbiology/pathology | 2 | 100.0 |
*Prostitution | 2 | 11.0 |
T-Lymphocyte Subsets | 2 | 1.0 |
Adenocarcinoma/*metabolism | 3 | 3.0 |
Receptors, Interleukin-2/analysis | 2 | 0.0 |
T-Lymphocytes/*immunology | 2 | 0.0 |
Blood Coagulation Factors/*metabolism | 2 | 2.0 |
Glucagon/analysis | 2 | 11.0 |
Antineoplastic Agents/*therapeutic use | 4 | 1.0 |
Hormones/*blood | 3 | 2.0 |
CA-15-3 Antigen | 2 | 2.0 |
Technetium Tc 99m Medronate/diagnostic use | 3 | 30.0 |
Prostate/enzymology/metabolism | 2 | 66.0 |
Adenocarcinoma/pathology | 3 | 3.0 |
Carcinoma, Squamous Cell/pathology | 2 | 4.0 |
Denmark | 2 | 1.0 |
Fetus | 2 | 0.0 |
Histological Techniques | 4 | 8.0 |
Antigens, Neoplasm/*blood | 18 | 40.0 |
Prostatic Neoplasms/*blood/therapy | 3 | 75.0 |
Tissue Polypeptide Antigen | 8 | 29.0 |
Adenocarcinoma/blood/pathology | 3 | 50.0 |
Carcinoma, Small Cell/blood/pathology | 2 | 66.0 |
Carcinoma, Squamous Cell/blood/pathology | 2 | 33.0 |
Lung Neoplasms/*blood/pathology | 2 | 33.0 |
Seminal Plasma Proteins | 33 | 80.0 |
Blood Pressure Determination/*methods | 2 | 20.0 |
*Echocardiography, Doppler | 2 | 40.0 |
Alkaline Phosphatase/analysis | 4 | 7.0 |
Antineoplastic Agents/therapeutic use | 4 | 1.0 |
*Imidazolidines | 3 | 15.0 |
Antigens, Tumor-Associated, Carbohydrate/blood | 2 | 13.0 |
Chorionic Gonadotropin/blood | 4 | 4.0 |
alpha-Fetoproteins/analysis | 6 | 2.0 |
Atrophy | 2 | 1.0 |
Prostatic Diseases/*pathology/physiopathology | 2 | 100.0 |
Poly A/genetics/isolation & purification | 2 | 5.0 |
RNA/genetics/isolation & purification | 2 | 1.0 |
Antifibrinolytic Agents/analysis | 2 | 12.0 |
Remission Induction | 5 | 0.0 |
African Americans | 2 | 1.0 |
Antibodies, Monoclonal/*diagnostic use | 7 | 3.0 |
Prostatic Neoplasms/*radionuclide imaging | 2 | 100.0 |
Life Tables | 2 | 1.0 |
Antigens, Viral/analysis | 3 | 3.0 |
Cervix Neoplasms/*microbiology | 2 | 50.0 |
Chlamydia trachomatis/isolation & purification | 2 | 28.0 |
Probability | 2 | 0.0 |
Prostate/metabolism | 4 | 5.0 |
Prostatic Hyperplasia/blood | 12 | 54.0 |
Histocytochemistry | 20 | 3.0 |
Antibodies, Monoclonal/*administration & dosage | 2 | 6.0 |
Iodine Radioisotopes/*diagnostic use | 2 | 3.0 |
Tissue Plasminogen Activator/analysis | 2 | 5.0 |
Dendritic Cells/*immunology | 2 | 0.0 |
Proteins/*secretion | 2 | 22.0 |
Antigens, Surface/analysis | 2 | 0.0 |
Semen/*chemistry/enzymology | 2 | 100.0 |
Prostate-Specific Antigen | 124 | 86.0 |
*Fimbriae, Bacterial | 2 | 40.0 |
Multigene Family | 2 | 0.0 |
*Papillomavirus | 3 | 50.0 |
Lysosomes/enzymology | 3 | 4.0 |
Prostatic Neoplasms/enzymology | 12 | 63.0 |
RNA, Neoplasm/genetics/isolation & purification | 2 | 3.0 |
*HIV Infections/complications/epidemiology/transmission | 2 | 100.0 |
HIV Seroprevalence | 2 | 11.0 |
Health Services Needs and Demand/*standards | 2 | 100.0 |
Primary Health Care/*standards | 2 | 33.0 |
Women's Health Services/*standards | 2 | 100.0 |
Antibodies, Monoclonal/*therapeutic use | 4 | 1.0 |
Antigens, Differentiation/analysis | 3 | 0.0 |
S100 Proteins/analysis | 2 | 1.0 |
Papillomavirus/*isolation & purification | 5 | 62.0 |
Prostatic Neoplasms/*diagnosis/therapy | 3 | 100.0 |
Neoplasm Metastasis/*diagnosis | 3 | 20.0 |
Prostatic Neoplasms | 2 | 3.0 |
Antigens, Neoplasm/genetics/*metabolism | 2 | 10.0 |
Dihydrotestosterone/pharmacology | 3 | 3.0 |
Estradiol/pharmacology | 3 | 1.0 |
Radioimmunoassay/methods | 8 | 5.0 |
Lymph Node Excision | 2 | 2.0 |
Phosphopyruvate Hydratase/analysis | 3 | 3.0 |
Basement Membrane/physiology | 2 | 18.0 |
Antigens, Neoplasm/*analysis | 72 | 18.0 |
*Ploidies | 3 | 4.0 |
Antigens, Neoplasm/blood | 5 | 23.0 |
Buserelin/*analogs & derivatives/therapeutic use | 2 | 40.0 |
Goserelin | 3 | 30.0 |
Prostatic Neoplasms/*diagnosis/drug therapy/mortality | 2 | 100.0 |
Culture Media | 2 | 0.0 |
DNA/biosynthesis | 2 | 0.0 |
Culture Techniques | 3 | 0.0 |
Adenocarcinoma/*immunology | 2 | 5.0 |
Prostatic Neoplasms/*immunology | 6 | 35.0 |
Cell Count | 2 | 0.0 |
Antibodies, Viral/analysis | 2 | 1.0 |
Acid Phosphatase/*urine | 3 | 75.0 |
Prostatic Hyperplasia/urine | 3 | 75.0 |
Prostatic Neoplasms/diagnosis/*therapy | 2 | 100.0 |
Blood Pressure | 6 | 0.0 |
Heart Catheterization | 4 | 6.0 |
Bone Neoplasms/diagnosis/radionuclide imaging/*secondary | 2 | 100.0 |
Fixatives | 6 | 8.0 |
Immunoglobulins/analysis | 3 | 1.0 |
Antigens, Neoplasm/*metabolism | 3 | 3.0 |
Carcinoembryonic Antigen/*analysis | 7 | 12.0 |
Prostatic Neoplasms/immunology/*pathology | 3 | 42.0 |
Macromolecular Substances | 2 | 0.0 |
Molecular Structure | 2 | 0.0 |
DNA Probes, HPV | 2 | 10.0 |
Papillomavirus/*genetics | 2 | 11.0 |
Prostate/enzymology/*immunology | 2 | 100.0 |
Macaca mulatta | 2 | 0.0 |
Antigens, Viral/*analysis | 5 | 10.0 |
Blood Flow Velocity | 2 | 2.0 |
Hypertension, Pulmonary/*physiopathology | 2 | 28.0 |
Pulmonary Artery/*physiology | 2 | 28.0 |
Prostatic Neoplasms/*blood/enzymology | 2 | 100.0 |
*Staining and Labeling/methods | 2 | 100.0 |
Diethylstilbestrol/therapeutic use | 4 | 44.0 |
Chromatography, Ion Exchange | 2 | 0.0 |
Spectrophotometry, Ultraviolet | 2 | 1.0 |
Prostatic Neoplasms/*blood/pathology | 4 | 40.0 |
Nigeria | 2 | 3.0 |
Epithelium/pathology | 3 | 2.0 |
Prostatic Neoplasms/*enzymology/pathology | 2 | 18.0 |
Prostatic Diseases/*diagnosis | 2 | 100.0 |
Glutathione Transferase/*analysis | 2 | 33.0 |
Tumor Virus Infections/*diagnosis/pathology | 2 | 100.0 |
Papillomavirus Infections/complications/*diagnosis | 2 | 66.0 |
Papillomavirus, Human/*pathogenicity | 2 | 22.0 |
Pregnancy Complications, Neoplastic/*diagnosis | 2 | 50.0 |
Prostate/*enzymology/immunology | 3 | 100.0 |
Prostatic Neoplasms/*diagnosis/immunology | 3 | 100.0 |
Drug Synergism | 2 | 0.0 |
Sexual Behavior | 2 | 2.0 |
Prostatic Hyperplasia/*surgery | 3 | 100.0 |
Prostatic Neoplasms/*surgery | 2 | 66.0 |
Osteocalcin/*blood | 2 | 9.0 |
Cervix Uteri/microbiology | 3 | 60.0 |
Papillomavirus/*genetics/isolation & purification | 2 | 50.0 |
Enzyme Tests | 7 | 10.0 |
Gonadorelin/analogs & derivatives/therapeutic use | 2 | 100.0 |
Antineoplastic Agents/pharmacology | 3 | 0.0 |
Prostatic Neoplasms/*enzymology/therapy | 2 | 100.0 |
Amino Acids/analysis | 6 | 2.0 |
Immunochemistry | 9 | 4.0 |
Drug Evaluation | 2 | 0.0 |
Smoking | 2 | 0.0 |
Antigens, Neoplasm/immunology | 2 | 1.0 |
Antigens, Surface/immunology | 2 | 1.0 |
Calcitonin/analysis | 2 | 8.0 |
Somatostatin/analysis | 2 | 3.0 |
Acid Phosphatase/*analysis/immunology | 2 | 50.0 |
Antibodies/immunology | 3 | 0.0 |
Antigens, Neoplasm/*analysis/immunology | 2 | 11.0 |
Proteins/*analysis/immunology | 2 | 25.0 |
*Staining and Labeling | 2 | 18.0 |
Carcinoma/*blood | 3 | 25.0 |
Prostatic Hyperplasia/enzymology/*immunology | 2 | 66.0 |
Prostatic Neoplasms/enzymology/*immunology | 6 | 85.0 |
Purpura, Thrombotic Thrombocytopenic/*blood | 2 | 28.0 |
Antigens, Neoplasm | 3 | 7.0 |
Reagent Kits, Diagnostic | 9 | 6.0 |
Ultrasonography | 2 | 2.0 |
Blood Proteins/analysis | 2 | 1.0 |
*Bone Marrow Transplantation | 2 | 0.0 |
Acid Phosphatase/immunology | 2 | 50.0 |
Cervix Neoplasms/*etiology/microbiology | 2 | 100.0 |
Erythrocytes/enzymology | 2 | 0.0 |
Indicators and Reagents | 2 | 0.0 |
Nitrophenols/metabolism | 2 | 9.0 |
Buserelin/therapeutic use | 2 | 40.0 |
Gonadorelin/*analogs & derivatives/therapeutic use | 2 | 33.0 |
Leuprolide | 2 | 20.0 |
Prostatic Neoplasms/blood | 3 | 37.0 |
DNA Transposable Elements | 2 | 1.0 |
DNA, Bacterial/genetics | 3 | 4.0 |
Escherichia coli/*genetics/pathogenicity | 2 | 100.0 |
*Genes, Bacterial | 2 | 2.0 |
Immune Sera | 6 | 2.0 |
Buserelin/*therapeutic use | 4 | 66.0 |
Pulmonary Artery/*physiopathology | 2 | 100.0 |
DNA/analysis | 2 | 0.0 |
Lysosomes/*enzymology | 3 | 6.0 |
Immunoglobulin G/analysis | 2 | 0.0 |
Genes, Bacterial | 4 | 3.0 |
Papillomavirus/*immunology | 2 | 33.0 |
Actuarial Analysis | 2 | 2.0 |
Prostate/*analysis | 2 | 33.0 |
Prostatic Neoplasms/*analysis | 3 | 75.0 |
Prostatic Hyperplasia/immunology | 3 | 100.0 |
Prostatic Neoplasms/*analysis/pathology | 2 | 66.0 |
*Blood Proteins | 5 | 6.0 |
Prostatitis/diagnosis | 3 | 60.0 |
Prostatic Neoplasms/*blood/immunology | 2 | 66.0 |
Semen/*analysis | 2 | 14.0 |
Adenocarcinoma/enzymology/pathology | 3 | 30.0 |
Prostate/*enzymology/pathology | 3 | 100.0 |
Prostatic Hyperplasia/enzymology/pathology | 2 | 66.0 |
Prostatic Neoplasms/enzymology/pathology | 2 | 40.0 |
Phosphoric Monoester Hydrolases/*blood | 2 | 28.0 |
Circadian Rhythm | 3 | 1.0 |
DNA Restriction Enzymes | 2 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Ferritin/*blood | 2 | 3.0 |
Fimbriae Proteins | 3 | 37.0 |
Tumor Stem Cell Assay | 2 | 1.0 |
Prostate/enzymology/*secretion | 2 | 66.0 |
Adenocarcinoma/immunology/*pathology | 2 | 13.0 |
Epithelium/analysis | 2 | 14.0 |
Prostatic Neoplasms/*drug therapy | 2 | 5.0 |
Semen/enzymology | 3 | 27.0 |
Neopterin | 2 | 2.0 |
Osteocalcin | 2 | 15.0 |
Prostate/*analysis/enzymology | 5 | 100.0 |
Neoplasms, Hormone-Dependent/analysis/enzymology | 2 | 100.0 |
Prostatic Neoplasms/*analysis/enzymology | 3 | 100.0 |
Prostatic Hyperplasia/enzymology/metabolism | 2 | 66.0 |
Antibodies, Monoclonal/*analysis | 2 | 4.0 |
Immunologic Techniques | 6 | 1.0 |
Neoplasms/immunology | 2 | 3.0 |
Prostatic Hyperplasia/enzymology/immunology | 2 | 100.0 |
Prostatic Hyperplasia/*immunology | 2 | 50.0 |
Epithelium/immunology | 2 | 1.0 |
Peptides/analysis | 2 | 2.0 |
Isoenzymes/*blood | 4 | 8.0 |
Immunosorbent Techniques | 3 | 1.0 |
Cell Fractionation | 2 | 0.0 |
Aniline Compounds/chemistry | 2 | 50.0 |
Plant Proteins/*chemistry/*pharmacology | 2 | 100.0 |
Receptors, Progesterone/analysis | 2 | 0.0 |
Immunodiffusion | 5 | 1.0 |
Isoelectric Focusing | 8 | 1.0 |
Semen/analysis | 2 | 22.0 |
Prolactin/blood | 2 | 0.0 |
Electrophoresis | 2 | 0.0 |
Liver Neoplasms/secondary | 2 | 3.0 |
*Histocytochemistry | 2 | 33.0 |
Bone and Bones/enzymology | 3 | 33.0 |
Colorimetry | 2 | 3.0 |
Liver/enzymology | 2 | 0.0 |
Isoenzymes/*metabolism | 2 | 0.0 |
Placenta/enzymology | 3 | 3.0 |
Counterimmunoelectrophoresis | 6 | 26.0 |
Glial Fibrillary Acidic Protein/*analysis | 2 | 4.0 |
Antibodies, Monoclonal/immunology | 3 | 0.0 |
Sodium/blood | 2 | 1.0 |
Cardiac Output/drug effects | 2 | 6.0 |
Binding, Competitive | 2 | 0.0 |
Epithelium/enzymology/ultrastructure | 2 | 66.0 |
Prostate/*enzymology/ultrastructure | 2 | 100.0 |
Trypsin | 5 | 3.0 |
Acid Phosphatase/*blood/immunology | 3 | 100.0 |
Immunoglobulins/*analysis | 6 | 6.0 |
Chromatography | 2 | 1.0 |
Follicle Stimulating Hormone/blood | 3 | 0.0 |
Simplexvirus/immunology | 2 | 9.0 |
Bone Marrow/metabolism | 2 | 1.0 |
Plasminogen Inactivators | 2 | 13.0 |
Carcinoma in Situ/pathology | 2 | 28.0 |
Cervix Dysplasia/pathology | 2 | 50.0 |
Creatine Kinase/*blood | 2 | 5.0 |
Isoenzymes | 6 | 3.0 |
Fimbriae, Bacterial/*physiology | 2 | 22.0 |
Cytoplasm/analysis | 2 | 9.0 |
Peptides/*analysis | 3 | 4.0 |
Staining and Labeling/methods | 2 | 1.0 |
Cell Nucleus/analysis | 2 | 9.0 |
Creatine Kinase/*analysis | 2 | 66.0 |
*Immunologic Techniques | 2 | 6.0 |
Epitopes/immunology | 3 | 0.0 |
Immunoelectrophoresis | 4 | 1.0 |
Immunoglobulin G/immunology | 2 | 0.0 |
*Counterimmunoelectrophoresis | 3 | 60.0 |
*Immunoelectrophoresis | 3 | 25.0 |
Organophosphorus Compounds | 2 | 16.0 |
*Radioimmunoassay | 4 | 10.0 |
Muramidase/analysis | 2 | 7.0 |
Iodine Radioisotopes/diagnostic use | 2 | 0.0 |
Radioimmunoassay/*methods | 4 | 5.0 |
Muramidase/*analysis | 3 | 33.0 |
Neoplasms/*enzymology | 2 | 5.0 |
Cell Membrane/immunology | 3 | 1.0 |
Factor VIII/analysis/*immunology | 2 | 25.0 |
Hodgkin Disease/*immunology | 2 | 7.0 |
Lymph Nodes/*immunology | 2 | 5.0 |
von Willebrand Factor | 2 | 7.0 |
Brain Neoplasms/*metabolism/pathology | 2 | 4.0 |
Glial Fibrillary Acidic Protein/*metabolism | 2 | 6.0 |
Oligodendroglioma/*metabolism/pathology | 2 | 22.0 |
*Fluorescent Antibody Technique | 3 | 12.0 |
Immunoglobulin A/analysis | 4 | 2.0 |
Prostatic Neoplasms/blood/*enzymology | 2 | 66.0 |
Gastrins/*analysis | 2 | 50.0 |
Immunoglobulin A/*analysis | 2 | 3.0 |
Carbohydrates/analysis | 2 | 3.0 |
B-Lymphocytes | 2 | 1.0 |
ABO Blood-Group System | 2 | 3.0 |
Immunoassay/*methods | 2 | 2.0 |
Nuclear Envelope/analysis | 2 | 66.0 |
*Antibodies, Monoclonal | 2 | 0.0 |
*Antigen-Antibody Complex | 2 | 3.0 |
Immunoglobulins, lambda-Chain/analysis | 2 | 12.0 |
Prostatic Diseases/enzymology | 2 | 100.0 |
Antigen-Antibody Complex | 2 | 1.0 |
Immunoglobulins, J-Chain/analysis | 2 | 33.0 |
Immunoglobulins, kappa-Chain/analysis | 2 | 9.0 |
Adenocarcinoma/enzymology | 2 | 15.0 |
Cytoplasm/immunology | 2 | 2.0 |
Leukocytes/*immunology | 2 | 1.0 |
Immunoglobulins, Light-Chain/*analysis | 2 | 33.0 |
Rabbits/immunology | 3 | 3.0 |
Nerve Tissue Proteins/*analysis | 2 | 2.0 |
Pregnancy Proteins/*biosynthesis | 2 | 11.0 |
Pregnancy-Specific beta 1-Glycoproteins/*biosynthesis | 2 | 20.0 |
Mitogen-Activated Protein Kinases/metabolism | 2 | 0.0 |
Isoenzymes/isolation & purification | 2 | 28.0 |
Antibodies | 3 | 0.0 |
Antigens | 2 | 2.0 |
Urogenital Neoplasms/*enzymology | 2 | 100.0 |
